NYSE - Delayed Quote USD

Edwards Lifesciences Corporation (EW)

76.28

+0.74

+(0.98%)

At close: April 29 at 4:00:02 PM EDT

75.40

-0.88

(-1.15%)

After hours: April 29 at 7:51:09 PM EDT

Dow Jones Aerospace Giant Boeing Nears Buy Point; Spotify Earnings Imminent

Dow Jones aerospace giant Boeing is approaching a new buy point, while Spotify earnings loom ahead of the market open Tuesday.

Investor's Business Daily yesterday

EW
+0.98%
SPOT

MELI
Edwards Shoots Higher As It Shrugs Off Tariffs Worries — Until 2026

Edwards stock shot higher Thursday after the medtech player said tariffs are likely to have little impact in 2025.

Investor's Business Daily 5 days ago

EW
+0.98%
Edwards Lifesciences (NYSE:EW) Projects 2025 Sales Over US$5.7 Billion With Strong Earnings

Edwards Lifesciences (NYSE:EW) recently announced its updated guidance, projecting second-quarter 2025 sales between $1.45 billion and $1.53 billion, alongside first-quarter results showing a rise in sales and net income compared to the previous year. This aligns with a broader market trend where the S&P 500 and Nasdaq Composite surged, driven by positive earnings reports and easing concerns over tariffs. The company's 2.2% price move over the last quarter reflects the general optimism but...

Simply Wall St. 5 days ago

EW
+0.98%
Texas Instruments, Mondelez downgraded: Wall Street's top analyst calls

Texas Instruments, Mondelez downgraded: Wall Street's top analyst calls

The Fly 5 days ago

TXN

MDLZ

TEL
Q1 2025 Edwards Lifesciences Corp Earnings Call

Q1 2025 Edwards Lifesciences Corp Earnings Call

Thomson Reuters StreetEvents 5 days ago

EW
+0.98%
Edwards shrugs off tariffs, backs 2025 profit forecast

The heart valve specialist saw better-than-expected TAVR sales in the first quarter as hospitals addressed capacity constraints that have dogged its core business.

MedTech Dive 5 days ago

EW
+0.98%
EW Q1 Earnings & Revenues Beat, Stock Climbs, '25 Sales View Raised

Edwards Lifesciences' first-quarter 2025 performance benefits from its differentiated portfolio of therapies to treat patients with structural heart disease.

Zacks 5 days ago

EW
+0.98%
Edwards Lifesciences Corp (EW) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ...

Edwards Lifesciences Corp (EW) reports an 8% increase in total sales, raises full-year guidance, and achieves significant product approvals in Q1 2025.

GuruFocus.com 5 days ago

EW
+0.98%
Edwards Lifesciences (EW) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Edwards Lifesciences (EW) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks 6 days ago

EW
+0.98%
Edwards Lifesciences Reports First Quarter Results

IRVINE, Calif., April 23, 2025--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Mar. 31, 2025.

Business Wire 6 days ago

EW
+0.98%
Intuitive, Boston Scientific and Edwards next up in medtech earnings

Tariff talk will continue in the second week of earnings season, but the updates could also shed light on trends and competitive dynamics in key markets.

MedTech Dive 8 days ago

BSX
+0.55%
EW
+0.98%
Edwards says eight-year data confirm long-term durability of Resilia tissue

Edwards Lifesciences (EW) announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary Resilia tissue technology have significantly improved long-term outcomes compared to those receiving non-Resilia tissue bioprosthetic valves. Presented at the Heart Valve Society Annual Meeting, the study of 947 patients marks the first long-term, propensity-matched comparison between Resilia tissue and non-Resilia tissue surgical aortic valves. The Resilia

TipRanks 10 days ago

EW
+0.98%
Unlocking Q1 Potential of Edwards Lifesciences (EW): Exploring Wall Street Estimates for Key Metrics

Evaluate the expected performance of Edwards Lifesciences (EW) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks 11 days ago

EW
+0.98%
Eight-Year Data Confirm Long-Term Durability of Edwards’ RESILIA Tissue

CAIRO, April 18, 2025--Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue technology have significantly improved long-term outcomes compared to those receiving non-RESILIA tissue bioprosthetic valves.

Business Wire 11 days ago

EW
+0.98%
Solid TMTT Growth to Drive Edwards Lifesciences' Q1 Earnings

EW's first-quarter 2025 performance is likely to have gained from growth drivers across its businesses amid macroeconomic headwinds.

Zacks 12 days ago

EW
+0.98%
Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025

IRVINE, Calif., April 16, 2025--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2025 after the market closes on Wednesday April 23, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results.

Business Wire 13 days ago

EW
+0.98%
Edwards receives CE mark for Sapien M3 mitral valve replacement device

The replacement system is launching into markets already served by repair devices, namely Edwards’ Pascal and Abbott’s Mitraclip.

MedTech Dive 15 days ago

EW
+0.98%
Edwards secures CE mark for transfemoral mitral valve implant

Edwards’ mitral valve implant approval in Europe mounts a challenge to long-time market dominator Abbott.

Medical Device Network 15 days ago

EW
+0.98%
GLDAF
Edwards SAPIEN M3 Receives CE Mark, Becoming World’s First Transfemoral Transcatheter Mitral Valve Replacement System

IRVINE, Calif., April 14, 2025--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of patients with symptomatic (moderate-to-severe or severe) mitral regurgitation (MR) who are deemed unsuitable for surgery or transcatheter edge-to-edge (TEER) therapy. Leveraging the company’s SAPIEN technology, the SAPIEN M3 system is the world's first approved transcatheter valve replacement therap

Business Wire 15 days ago

EW
+0.98%
Edwards Lifesciences (NYSE:EW) Presents Promising AS Treatment Data At ACC Session

Edwards Lifesciences (NYSE:EW) recently announced significant findings at the ACC Annual Scientific Session, showcasing crucial research in the treatment of structural heart disease. This development, alongside data indicating the increased effectiveness of electronic notifications in treating severe aortic stenosis, comes amid broader market volatility. The past week saw a 1.58% rise in Edwards Lifesciences' stock, contrasting with a 3.4% drop in the overall market as concerns about tariffs...

Simply Wall St. 28 days ago

EW
+0.98%

Performance Overview

Return	EW	S&P 500 (^GSPC)
YTD	+3.04%	-5.45%
1-Year	-11.25%	+8.69%
3-Year	-27.89%	+34.58%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Edwards Lifesciences Corporation (EW)

Dow Jones Aerospace Giant Boeing Nears Buy Point; Spotify Earnings Imminent

Edwards Shoots Higher As It Shrugs Off Tariffs Worries — Until 2026

Edwards Lifesciences (NYSE:EW) Projects 2025 Sales Over US$5.7 Billion With Strong Earnings

Texas Instruments, Mondelez downgraded: Wall Street's top analyst calls

Q1 2025 Edwards Lifesciences Corp Earnings Call

Edwards shrugs off tariffs, backs 2025 profit forecast

EW Q1 Earnings & Revenues Beat, Stock Climbs, '25 Sales View Raised

Edwards Lifesciences Corp (EW) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ...

Edwards Lifesciences (EW) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

Edwards Lifesciences Reports First Quarter Results

Intuitive, Boston Scientific and Edwards next up in medtech earnings

Edwards says eight-year data confirm long-term durability of Resilia tissue

Unlocking Q1 Potential of Edwards Lifesciences (EW): Exploring Wall Street Estimates for Key Metrics

Eight-Year Data Confirm Long-Term Durability of Edwards’ RESILIA Tissue

Solid TMTT Growth to Drive Edwards Lifesciences' Q1 Earnings

Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025

Edwards receives CE mark for Sapien M3 mitral valve replacement device

Edwards secures CE mark for transfemoral mitral valve implant

Edwards SAPIEN M3 Receives CE Mark, Becoming World’s First Transfemoral Transcatheter Mitral Valve Replacement System

Edwards Lifesciences (NYSE:EW) Presents Promising AS Treatment Data At ACC Session

Performance Overview